Kingworld Medicines Group 관리
관리 기준 확인 3/4
현재 CEO에 대한 정보가 충분하지 않습니다.
주요 정보
Li Sheng Zhao
최고 경영자
CN¥1.5m
총 보상
| CEO 급여 비율 | 98.5% |
| CEO 임기 | 16.2yrs |
| CEO 소유권 | 54.2% |
| 경영진 평균 재임 기간 | 데이터 없음 |
| 이사회 평균 재임 기간 | 14yrs |
최근 관리 업데이트
Recent updates
The Returns On Capital At Kingworld Medicines Group (HKG:1110) Don't Inspire Confidence
Nov 13
Kingworld Medicines Group (HKG:1110) Takes On Some Risk With Its Use Of Debt
Oct 04Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To CN¥0.0338
May 31Even With A 26% Surge, Cautious Investors Are Not Rewarding Kingworld Medicines Group Limited's (HKG:1110) Performance Completely
May 22Investors Shouldn't Be Too Comfortable With Kingworld Medicines Group's (HKG:1110) Earnings
Apr 29Kingworld Medicines Group (HKG:1110) Will Pay A Larger Dividend Than Last Year At CN¥0.0338
Apr 23A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)
Mar 22The Return Trends At Kingworld Medicines Group (HKG:1110) Look Promising
Nov 30Slowing Rates Of Return At Kingworld Medicines Group (HKG:1110) Leave Little Room For Excitement
Aug 17Kingworld Medicines Group (HKG:1110) Will Pay A Larger Dividend Than Last Year At CN¥0.0247
May 30The Returns At Kingworld Medicines Group (HKG:1110) Aren't Growing
May 11Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To CN¥0.0247
Apr 03Returns On Capital At Kingworld Medicines Group (HKG:1110) Paint A Concerning Picture
Feb 07A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)
Oct 07Kingworld Medicines Group's (HKG:1110) Returns On Capital Not Reflecting Well On The Business
Jul 05Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To HK$0.024
Apr 27We Like These Underlying Return On Capital Trends At Kingworld Medicines Group (HKG:1110)
Aug 17Kingworld Medicines Group (HKG:1110) Seems To Use Debt Rather Sparingly
Apr 24Returns On Capital Are Showing Encouraging Signs At Kingworld Medicines Group (HKG:1110)
Mar 29Kingworld Medicines Group's (HKG:1110) Shareholders Are Down 46% On Their Shares
Mar 08Are Insiders Buying Kingworld Medicines Group Limited (HKG:1110) Stock?
Feb 15Should You Or Shouldn't You: A Dividend Analysis on Kingworld Medicines Group Limited (HKG:1110)
Jan 25
Will the Promising Trends At Kingworld Medicines Group (HKG:1110) Continue?
Dec 18We Think Kingworld Medicines Group (HKG:1110) Can Stay On Top Of Its Debt
Dec 05What We Learned About Kingworld Medicines Group's (HKG:1110) CEO Compensation
Nov 22CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CN¥31m |
| Mar 31 2024 | n/a | n/a | CN¥35m |
| Dec 31 2023 | CN¥1m | CN¥1m | CN¥38m |
| Sep 30 2023 | n/a | n/a | CN¥37m |
| Jun 30 2023 | n/a | n/a | CN¥36m |
| Mar 31 2023 | n/a | n/a | CN¥29m |
| Dec 31 2022 | CN¥1m | CN¥1m | CN¥23m |
| Sep 30 2022 | n/a | n/a | CN¥29m |
| Jun 30 2022 | n/a | n/a | CN¥35m |
| Mar 31 2022 | n/a | n/a | CN¥33m |
| Dec 31 2021 | CN¥1m | CN¥1m | CN¥30m |
| Sep 30 2021 | n/a | n/a | CN¥26m |
| Jun 30 2021 | n/a | n/a | CN¥21m |
| Mar 31 2021 | n/a | n/a | CN¥17m |
| Dec 31 2020 | CN¥1m | CN¥1m | CN¥12m |
| Sep 30 2020 | n/a | n/a | CN¥16m |
| Jun 30 2020 | n/a | n/a | CN¥20m |
| Mar 31 2020 | n/a | n/a | CN¥32m |
| Dec 31 2019 | CN¥2m | CN¥2m | CN¥43m |
| Sep 30 2019 | n/a | n/a | CN¥45m |
| Jun 30 2019 | n/a | n/a | CN¥46m |
| Mar 31 2019 | n/a | n/a | CN¥44m |
| Dec 31 2018 | CN¥1m | CN¥1m | CN¥41m |
| Sep 30 2018 | n/a | n/a | CN¥49m |
| Jun 30 2018 | n/a | n/a | CN¥56m |
| Mar 31 2018 | n/a | n/a | CN¥54m |
| Dec 31 2017 | CN¥2m | CN¥1m | CN¥51m |
보상 대 시장: Li Sheng 의 총 보상 ($USD 200.51K )은 Hong Kong 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 233.02K ).
보상과 수익: Li Sheng 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Li Sheng Zhao (66 yo)
16.2yrs
테뉴어
CN¥1,452,000
보상
Mr. Li Sheng Zhao is a Co-founder of Kingworld Medicines Group Limited and serves as its Chief Executive Officer. Mr. Zhao is responsible for Kingworld Medicines Group's overall strategic planning and busi...
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Co-Founder | 16.2yrs | CN¥1.45m | 54.21% HK$ 138.3m | |
| Co-Founder & Executive Director | 16.2yrs | CN¥1.32m | 15.25% HK$ 38.9m | |
| Executive Director | 15.3yrs | CN¥483.00k | 0.45% HK$ 1.2m | |
| Independent Non-Executive Director | 14yrs | CN¥285.00k | 0.036% HK$ 91.1k | |
| Independent Non-Executive Director | 14yrs | CN¥285.00k | 데이터 없음 | |
| Independent Non-Executive Director | 11.3yrs | CN¥285.00k | 0.042% HK$ 106.6k | |
| Independent Non-Executive Director | less than a year | 데이터 없음 | 데이터 없음 |
14.0yrs
평균 재임 기간
61yo
평균 연령
경험이 풍부한 이사회: 1110 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 14 년).